YKYukitsuka Kudo

Yukitsuka Kudo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yukitsuka Kudo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 March 2016
      • Vol. 74  (3) , 404-9

    [Tau imaging].

    by Yukitsuka Kudo, Shozo Furumoto, Ryuichi Harada, Nobuyuki Okamura

    Several promising tau imaging probes have been developed by Tohoku University ([18F]THK series), National Institute of Radiological Sciences([11C]PBB3), Eli Lilly ([18F]T807), and Hoffman-La Roche ([18F]R06958948). In this paper we discussed some of the criteria required for the tau imaging probe in Alzheimer's disease. It will be certain that tau imaging plays an important role in an accurate diagnosis and as companion diagnostics.

    • 1 March 2016
      • Vol. 74  (3) , 411-6

    [The trend of developing new disease-modifying drugs in Alzheimer's disease].

    by Hiroyuki Arai, Katsutoshi Furukawa, Naoki Tomita, Aiko Ishiki, Nobuyuki Okamura, Yukitsuka Kudo

    Development of symptomatic treatment of Alzheimer s disease by cholinesterase inhibitors like donepezil was successful. However, it is a disappointment that development of disease-modifying drugs such as anti-amyloid drug based on amyloid-cascade theory has been interrupted or unsuccessful. Therefore, we have to be more cautious regarding inclusion criteria for clinical trials of new drugs. We agree that potentially curative drugs should be started before symptoms begin as a preemptive therapy or prevention trial. The concept of personalized medicine also is important when ApoE4-related amyloid reducing therapy is considered. Unfortunately, Japanese-ADNI has suffered a setback since 2014. However, Ministry of Health, Labour and Welfare gave a final remark that there was nothing wrong in the data managing process in the J-ADNI data center. We should pay more attention to worldwide challenges of speeding up new drug development.

  • Open Access

    Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

    by Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, et al.

    Introduction: The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies have demonstrated significantly higher cortical retention of 18F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick’s disease (PiD). Methods: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescence studies in serial brain sections taken from individuals with AD (n = 3), CBD (n = 2), PSP (n = 1), PiD (n = 2) and Parkinson’s disease (PD; n = 2). In addition to the neuropathological analysis, one PSP patient had undergone a 18F-THK523 PET scan 5 months before death. Results: Although THK523 labelled tau-containing lesions such as neurofibrillary tangles and neuropil threads in the hippocampus and frontal regions of AD brains, it failed to label tau-containing lesions in non-AD tauopathies. Furthermore, though THK523 faintly labelled dense-cored amyloid-β plaques in the AD frontal cortex, it failed to label α-synuclein-containing Lewy bodies in PD brain sections. Conclusion: The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.


  • Open Access

    Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans

    by Miho Shidahara, Manabu Tashiro, Nobuyuki Okamura, Shozo Furumoto, Katsutoshi Furukawa, Shoichi Watanuki, Kotaro Hiraoka, Masayasu Miyake, Ren Iwata, Hajime Tamura, et al.

    The biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe ([18F] FACT) was investigated in humans.


    • 1 October 2011
      • p. 556-60

    [In vivo amyloid imaging using BF-227].

    by Nobuyuki Okamura, Ryuichi Harada, Shozo Furumoto, Kazuhiko Yanai, Yukitsuka Kudo

  • Quantitative Analysis of Amyloid ß Deposition in Patients with Alzheimer’s Disease Using Positron Emission Tomography

    by Manabu Tashiro, Nobuyuki Okamura, Shoichi Watanuki, Shozo Furumoto, Katsutoshi Furukawa, Yoshihito Funaki, Ren Iwata, Yukitsuka Kudo, Hiroyuki Arai, Hiroshi Watabe, et al.

    These findings suggest that [11C]BF-227 is a promising PET probe for clinical evaluation of early Aß deposition in AD patients.

  • Noninvasive Detection of Misfolded Proteins in the Brain Using [11C]BF-227 PET

    by Nobuyuki Okamura, Shozo Furumoto, Manabu Tashiro, Katsutoshi Furukawa, Hiroyuki Arai, Yukitsuka Kudo, Kazuhiko Yanai

    Alzheimer’s disease (AD) and many other neurodegenerative disorders belong to the family of protein misfolding diseases. These diseases are characterized by the deposition of insoluble protein aggregates containing an enriched ß-sheet structure. To evaluate PET amyloid-imaging tracer [11C]BF-227 as an agent for in vivo detection of various kinds of misfolded protein, a [11C]BF-227 PET study was performed in patients with various protein misfolding diseases, including AD, frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Sträussler-Scheinker disease (GSS). BF-227 binds to ß-amyloid fibrils with high affinity. Most of the AD patients showed prominent retention of [11C]BF-227 in the neocortex. In addition, neocortical retention of BF-227 was observed in the subjects with mild cognitive impairment who converted to AD during follow-up. DLB patients had elevated [11C]BF-227 uptake in the neocortex. However, FTD and sCJD patients showed no cortical retention of [11C]BF-227. Patients with multiple system atrophy had elevated BF-227 binding in the putamen. Finally, GSS patients had elevated BF-227 uptake in the cerebellum and other brain regions. This chapter confirms that BF-227 can selectively bind to a-synuclein and prion protein deposits using postmortem brain samples. Based on these findings, [11C]BF-227 is not necessarily specific for ß-amyloid in AD patients. However, this tracer could be used to detect various types of protein aggregates in the brain.

  • Imaging Amyloid Pathology in the Living Brain

    by Nobuyuki Okamura, Shozo Furumoto, Hiroyuki Arai, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo

    Progressive deposition of amyloid plaques in the brain, which begins before the appearance of cognitive decline, is an initiating event in the pathogenesis of Alzheimers disease. Therefore, noninvasive detection of amyloid pathology is important for presymptomatic diagnosis and preventive therapy for Alzheimers disease. Recent research advances have enabled the in vivo imaging of amyloid pathology in humans using nuclear medicine technology. Several amyloid-binding agents have been developed and evaluated by positron emission tomography (PET) and single photon emission computed tomography (SPECT) for their use as contrast agents. Available clinical evidence indicates that amyloid imaging enables the early diagnosis of Alzheimers disease with high accuracy and suggests its usefulness for the prediction of progression to Alzheimers disease in subjects with mild cognitive impairment and probably also in cognitively normal individuals. Another application of this technology is as a surrogate marker for monitoring brain amyloid. In this review, we describe recent progress in the development of amyloid imaging technology and human clinical trials.


    • 1 February 2007
      • Vol. 65  (2) , 320-6

    [Alzheimer' s disease].

    by Nobuyuki Okamura, Shozo Furumoto, Yukitsuka Kudo, Kazuhiko Yanai

    Progressive accumulation of amyloid plaques in the brain is a characteristic pathological change in Alzheimer's disease (AD) and precedes the presentation of cognitive impairment. In vivo detection of amyloid deposits using molecular imaging technique would thus prove useful for early diagnosis of AD and tracking disease progression. Several imaging agents have been developed that can noninvasively detect amyloid plaques in the brain and successfully differentiated AD patients from healthy normal individuals using positron emission tomography. Although validation remains required as to whether retention of these agents in the neocortex truly reflects the level of amyloid deposition, such findings suggest the potential usefulness of amyloid imaging technique for early diagnosis of AD.